Tumor lymphocyte infiltration is associated with favorable prognosis in early triple-negative and human epidermal growth factor receptor type 2 (HER2)-positive breast cancer phenotypes [1–4] and may influence the response to systemic therapies [3–6]. The gene discussed is ERBB2; the disease is breast cancer.